No description
No description

CREATIC aims to contribute in the field of pharmacoeconomic evaluation of orphan drugs, in particular to sustainably improve access to therapies that can make a major impact on the lives of patients with these specific diseases.

No description

Pharmacoeconomics in rare diseases is associated with challenges and factors arising from the limited prevalence and very specific characteristics of these diseases.

Pharmacoeconomics in the context of rare diseases addresses many specificities:

  • Limited data and studies
  • High research and development costs
  • Individual approach to patients
  • Benefits for patients and society
  • Issues related to benefit assessment
No description

Our mission in the field of pharmacoeconomic evaluation of orphan drugs is to find innovative and individualized approaches to assess the cost and effectiveness of therapies.

Given the specificities of rare diseases and the difficulties associated with the application of standard technology assessment (HTA) procedures, we focus on the following key aspects:

  • • Development of alternative methodologies
  • • Assessment of overall benefit
  • • Taking socio-economic aspects into account
  • • Dialogue with stakeholders
  • • Promoting innovative approaches to funding

Our expertise in pharmacoeconomics includes

  • Healt-Technology Assessment
  • Comparative Effectiveness Research
  • Cost-Effectiveness Analysis
  • Real-World Data (RWD) Assessement
No description

You are running an old browser version. We recommend updating your browser to its latest version.

More info